Is ustekinumab more effective than secukinumab for treating plaque psoriasis?

Secukinumab is Superior to Ustekinumab for Plaque Psoriasis

For moderate-to-severe plaque psoriasis, secukinumab demonstrates superior efficacy compared to ustekinumab, achieving higher rates of complete skin clearance and faster symptom relief, with comparable safety profiles. This recommendation is based on direct head-to-head comparison trials and is supported by the 2019 AAD-NPF guidelines 1.

Evidence from Direct Comparison Studies

The evidence strongly favors secukinumab based on two major head-to-head trials:

CLEAR Study Results:

• At week 16, secukinumab achieved 79% PASI 90 response versus 57.6% with ustekinumab 1
• This superiority was maintained through 52 weeks 2

CLARITY Study Results:

• At week 52, secukinumab achieved 73.2% PASI 90 versus 59.8% with ustekinumab (OR 1.84, P < 0.0001) 2
• IGA 0/1 (clear/almost clear skin): 76.0% versus 60.2% (OR 2.12, P < 0.0001) 2
• Secukinumab showed superiority as early as week 4 and maintained this advantage throughout treatment 3

Speed of Response

Secukinumab works significantly faster:

• Complete relief of itching: 4 weeks faster (P < 0.001) 4
• Complete relief of scaling: 8 weeks faster (P < 0.001) 4
• Time to PASI 50: 2.8 weeks with secukinumab versus 6.3 weeks with ustekinumab 5

This rapid response is clinically meaningful for patients suffering from active symptoms.

Quality of Life Benefits

Secukinumab provides superior quality of life improvements:

• DLQI 0/1 (no impact on quality of life) at week 52: 69.9% versus 61.2% (P = 0.0028) 2
• Time to DLQI response: 4 weeks faster with secukinumab (P < 0.0001) 4
• Greater cumulative benefit over 52 weeks in all patient-reported outcomes 4

Guideline Recommendations

Both medications receive Grade A recommendations from the 2019 AAD-NPF guidelines for moderate-to-severe plaque psoriasis 1. However:

Secukinumab dosing:

• 300 mg at weeks 0,1,2,3, and 4, then every 4 weeks 1
• The 300 mg dose is more effective than 150 mg (Grade A) 1

Ustekinumab dosing:

• Weight-based: 45 mg if ≤100 kg, 90 mg if >100 kg 1
• Given at weeks 0,4, then every 12 weeks 1

Special Populations

Secukinumab has stronger evidence for:

• Palmoplantar plaque psoriasis (Grade A) 1 versus ustekinumab (Grade B) 1
• Nail psoriasis (Grade A for both) 1
• Scalp psoriasis (Grade B) 1 versus ustekinumab (Grade C) 1

Asian populations: Secukinumab showed sustained and superior efficacy with faster response in Asian subgroup analysis 5

Psoriatic Arthritis Consideration

Important caveat: If the patient has concomitant psoriatic arthritis, the decision becomes more nuanced:

• Both have Grade A recommendations for PsA 1
• However, ustekinumab is noted as "less effective than TNF-α inhibitors for PsA" 1
• Ustekinumab lacks FDA labeling for prevention of joint destruction 1
• TNF-α inhibitors should be considered preferred for patients with PsA 1

Safety Profile

Both medications have comparable safety profiles:

• Infection rates are similar between the two agents 2, 3
• Serious adverse events are comparable 2, 3
• Real-world data confirms no significant safety differences 6, 7
• Secukinumab may have slightly higher rates of allergic reactions 7

Drug Survival and Adherence

Real-world data shows:

• Guselkumab has the highest drug survival, followed by secukinumab and ustekinumab with similar rates 7
• Secukinumab retention rate: 95.7% versus ustekinumab 84.6% at 52 weeks 5
• Female patients and those with hypertension have shorter drug survival regardless of agent 7

Clinical Algorithm

Choose secukinumab when:

• Primary goal is rapid and complete skin clearance
• Patient has nail, scalp, or palmoplantar involvement
• Patient prioritizes quality of life improvement
• No significant psoriatic arthritis present

Consider ustekinumab when:

• Patient prefers less frequent dosing (every 12 weeks vs every 4 weeks)
• Cost considerations favor ustekinumab
• Patient has failed secukinumab previously

Choose TNF-α inhibitor instead when:

• Patient has active psoriatic arthritis requiring joint protection
• Prevention of radiographic joint damage is a priority

Common Pitfalls

1. Don't assume equivalent efficacy - The head-to-head trials clearly demonstrate secukinumab superiority
2. Don't overlook dosing frequency - Secukinumab requires monthly maintenance versus quarterly for ustekinumab, which affects adherence
3. Don't ignore PsA screening - Always assess for joint involvement before selecting therapy
4. Don't use weight-based dosing for secukinumab - Unlike ustekinumab, secukinumab uses fixed 300 mg dosing